CMS Proposal On Part D May Address Drug Costs, But Will It Target Prices?
Upcoming proposed rule on Medicare Part D and Medicare Advantage prompts speculation about whether CMS is planning new measures to control spending on prescription drugs.
You may also be interested in...
Secretary Price will be succeeded on an acting basis by HHS acting assistant secretary for health Donald Wright, and everything from development of the executive order on drug pricing to pending Medicare reimbursement experiments could see a pause as part of the transition.
Lilly CEO David Ricks reflects on the state of play on drug pricing issues on Capitol Hill and in the Administration and the challenges he sees ahead.
Medicare payments to hospitals for drugs provided under the 340B program would be reduced to average sales price (ASP) minus 22.5%, which CMS believes is more closely aligned with the discounted price obtained by the providers.